HAE · Haemonetics Corporation

Haemonetics delivered Q4 FY2026 revenue of $346.4 million, a 4.8% increase year-over-year, driven by 8.0% growth in Hospital ($159.6M), 2.8% in Plasma ($130.3M), and 0.7% in Blood Center ($56.4M). Organic growth accelerated to 4.5%, and organic ex-CSL reached 8.6%, reflecting strength in core platforms excluding CSL Plasma transitional sales and Whole Blood divestiture impacts. CEO Chris Simon highlighted outperformance in Plasma and Blood Management Technologies, sequential Interventional Technologies improvement, and completion of a four-year plan building a diversified business.

GAAP results showed a net loss of $20.1 million or $(0.44) per share, versus prior-year income of $58.0 million or $1.17, due to a $221.2 million operating expense increase from Attune Medical intangible impairments and unrecoverable pre-acquisition inventory charges, yielding a -6.6% operating margin. Adjusted metrics remained resilient: gross margin 59.7% (down 50 bps from mix, tariffs, offset by volume/pricing), operating income $84.5 million (+2.6%), and EPS $1.29 (+4.0%). Full-year FY2026 revenue was $1.334 billion (-2.0%), with adjusted EPS $4.96.

Balance sheet cash stood at $245.4 million, down due to Vivasure acquisition and $100 million share repurchases (1.58M shares via 10b5-1 and ASR with Goldman Sachs). FY2027 guidance projects 3-6% organic growth (mid-single-digit Plasma/Hospital gains, Blood Center decline), 50-100 bps adjusted margin expansion, EPS growth comparable to revenue, and ~80% free cash flow conversion, signaling sustained momentum and execution focus.